CDSCO Certification in India for Medical Device, Drugs, and Cosmetics (2026 Update)

When you first hear the term “CDSCO certification,” it sounds simple. One approval. One certificate. One formality before business begins. That assumption usually lasts until you actually try to apply.

In 2026 CDSCO certification is no longer a surface-level compliance task. It is a layered regulatory process that depends entirely on what your product is, how it is used, where it is made and how it enters the Indian market. If you misunderstand even one of these points, your application does not fail loudly. It stalls. Quietly. For months.

This article is meant to slow things down for you. To explain CDSCO certification as it exists today, not as it is marketed. You will not find shortcuts here. What you will find is clarity.

CDSCO stands for the Central Drugs Standard Control Organisation. This organisation comes under the Ministry of Health and Family Welfare Government of India. Its mandate is public health protection. Everything else flows from that

When people talk about CDSCO certification they are usually referring to one of the following:

• A manufacturing licence
• An import licence
• A registration certificate
• A central approval for a regulated product

There is no one document that is called a "CDSCO certificate" that applies to everyone. The Drugs and Cosmetics Act of 1940 and the rules made under it say that each type of product must follow its own legal path.

This means that your duties change depending on whether you sell medical devices, drugs, or cosmetics.

In practice this means that your obligations change depending on whether you deal in medical devices, pharmaceutical drugs or cosmetics.

If you have spoken to older manufacturers, you may hear stories about approvals that moved quickly or were “managed.” That environment no longer exists.

By 2026 CDSCO has shifted heavily toward digital scrutiny. Applications are filed online. Documents are validated automatically. Reviewers follow checklists. Deviations are flagged early.

More importantly, the regulator’s tolerance for incomplete or loosely prepared submissions has dropped sharply. The focus is now on first-time accuracy.

This is not about making life difficult for businesses. It is about traceability, accountability and safety. Once you see it from that angle the strictness makes sense.

Medical devices are regulated under the Rules set in 2017. These rules brought structure to a sector that was earlier fragmented

If you are dealing with devices the first thing you must understand is classification. Everything else depends on it

Based on risk devices are divided into four classes:

• Class A devices are low risk.
• Class B devices carry slightly higher risk.
• Class C devices involve moderate to high risk.
• Class D devices are high risk.

This classification is not something you choose for convenience. It is determined by intended use, duration of contact with the body, invasiveness, and potential harm if the device fails.

Many applications fail because businesses classify their products based on what they think is reasonable, not on what the rules say.

In India, medical device approvals are split between state authorities and CDSCO.

For Class A and Class B devices manufactured in India, state licensing authorities generally handle approvals.

For Class C and Class D devices, and for all imported medical devices regardless of class, approval comes directly from CDSCO through the SUGAM portal.

This distinction matters because the documentation depth, review time, and scrutiny level increase significantly once CDSCO is involved centrally.

By 2026, CDSCO expects more than a product brochure. At minimum, you are expected to submit:

• A clear statement of intended use
• A justification for classification
• Technical specifications and design details
• Quality system documentation
• Evidence of compliance with applicable standards
• Clinical or performance data where required

For imported devices, details of the overseas manufacturing site are reviewed carefully. CDSCO expects consistency between what you submit and what is already available in international regulatory databases.

Pharmaceutical drugs remain the most tightly controlled category under CDSCO. The reason is simple. Drugs act directly on the human body. Errors have consequences.

If you manufacture drugs in India your certification involves both state drug authorities and CDSCO depending on the product type. New drugs, biologicals, vaccines and certain therapeutic categories require central approval

The review is not limited to the product. CDSCO evaluates your manufacturing environment, quality control systems, staffing, and documentation practices.

For imports, the process becomes even more structured. CDSCO requires registration of the foreign manufacturing site and separate registration of each drug. One registration does not cover multiple products unless explicitly allowed.

This is where many importers underestimate the effort involved

Cosmetics are frequently treated as low-risk consumer goods. From a regulatory perspective that is not entirely true.

In India imported cosmetics require CDSCO registration before they can enter the market. This includes products like creams, lotions, makeup, perfumes and hair care items

The registration process focuses on safety, ingredient compliance and labelling accuracy. CDSCO checks whether any prohibited or restricted substances are used and whether labels meet Indian standards

If you import cosmetics without registration, consignments are stopped at ports. There is no flexibility on this point in 2026

Cosmetics manufactured in India require state licences but they must still align with standards prescribed under CDSCO-linked rules.

It is tempting to think that approvals are delayed because rules are complex. In reality most delays happen because documentation is poorly prepared

Common issues include:

• Mismatch between intended use and technical description
• Incomplete authorisation letters
• Missing declarations or undertakings
• Incorrect application forms
• Documents uploaded in wrong formats
• Inconsistent information across files

CDSCO reviewers do not “fix” these issues for you. They raise queries. Each query adds time. In some cases, applications are returned without detailed explanation.

This is why preparation matters more than speed.

All central CDSCO applications are filed through the SUGAM portal. It is not just a submission interface. It is a regulatory tracking system.

SUGAM validates fields, checks attachments, records timelines, and logs every communication. If something is missing the application does not move forward

One important point many applicants miss is version control. Once a document is uploaded, changes must be tracked carefully. Uploading a corrected document without explanation can create confusion instead of resolving it.

Knowing how to work with SUGAM is a skill in itself.

Many businesses relax once approval comes through. That is a mistake.

CDSCO certification comes with ongoing obligations. You are expected to:

• Maintain records for inspection
• Report adverse events when applicable
• Inform CDSCO of changes in manufacturing or sourcing
• Pay retention fees where required
• Renew approvals within prescribed timelines

In 2026 CDSCO actively monitors post-approval compliance. Lapsed licences and unreported changes are treated seriously.

Certification is not a one-time event. It is an ongoing relationship with the regulator.
 

On paper, CDSCO allows self-application. In practice, very few businesses succeed without expert support, especially for complex products.

A good consultant does not just submit forms. They interpret regulations. They anticipate questions. They structure documentation so that reviewers can understand it easily.

More importantly, they prevent mistakes before they happen.

Not all consultants work the same way. Many focus on volume. Agile Regulatory focuses on accuracy.

Their approach starts with understanding your product in detail. Only then do they map it to the correct regulatory pathway. This reduces rework and avoids misclassification, which is the most expensive mistake in CDSCO filings.

Agile Regulatory supports certification for:

• Medical devices across all risk classes
• Drug manufacturing and imports
• Cosmetic registration and licensing
• Amendments, renewals, and post-approval compliance

Their strength lies in preparation not promises. That is why they are considered a reliable CDSCO certification partner in India.

Before you file any CDSCO application, take time to do the following:

• Clarify your product’s intended use in writing.
• Confirm classification using official rules, not assumptions.
• Prepare documentation before opening the portal
• Review labelling requirements early.
• Understand post-approval obligations not just approval steps

These steps cost time upfront. They save months later.

It's not about filling out forms quickly to get CDSCO certification in India in 2026. It means knowing the rules, making sure that all the paperwork is correct and staying in compliance over time

If you approach the process casually delays are inevitable. If you approach it carefully with the right guidance, approvals become predictable

For businesses that want clarity instead of confusion and compliance instead of corrections, Agile Regulatory offers structured, dependable support for CDSCO certification across medical devices, drugs and cosmetics. Accuracy lasts longer than speed,